The drug bargaining game: Pharmaceutical regulation in Australia

Journal of Health Economics

Volumn 23, Issue 4, 2004, Pages 785-813

  Wright, Donald J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

I18; L51; Pharmaceutical regulation

Indexed keywords

NEW DRUG;

BARGAINING; PHARMACEUTICAL INDUSTRY; PROFITABILITY; REGULATORY APPROACH;

CONSUMER; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; HEALTH CARE UTILIZATION; MATHEMATICAL ANALYSIS; PATENT; PHARMACIST; QUALITY CONTROL; REVIEW; THEORETICAL MODEL;

EID: 4344640349     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2003.11.003     Document Type: Article

References (17)

1. Anis H., Wen Q. Price regulation of pharmaceuticals in Canada. Journal of Health Economics. 17:1998;21-38
2. Berndt E. International comparisons of pharmaceutical prices: what do we know, and what does it mean? Journal of Health Economics. 19:2000;283-287
3. Birkett D.J., Mitchell A.S., McManus P. A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Affairs. 20:2001;104-114
4. Danzon P., Chao L. Cross-national price differences for pharmaceuticals: how large, and why? Journal of Health Economics. 19:2000a;159-195
5. Danzon P., Chao L. Does regulation drive out competition in pharmaceutical markets? Journal of Law and Economics. 43:2000b;311-357
6. Johannesson M. The Australian guidelines for subsidisation of pharmaceuticals. PharmacoEconomics. 5:1992;355-362
7. Johnston, M., Zeckhauser, R., 1991. The Australian pharmaceutical subsidy gambit: transmuting deadweight loss and oligopoly rents to consumer surplus. NBER Working Paper #3783.
8. Krishna V., Serrano R. Multilateral bargaining. Review of Economic Studies. 63:1996;61-80
9. Laupacis A. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? Canadian Medical Association Journal. 166:2002;44-47
10. Lu Z., Comanor W. Strategic pricing of new pharmaceuticals. Review of Economics and Statistics. 80:1998;108-118
11. Mussa M., Rosen S. Monopoly and product quality. Journal of Economic Theory. 18:1978;301-317
12. Pavcnik N. Do pharmaceutical prices respond to potential patient out-of-pocket expenses? Rand Journal of Economics. 33:2002;469-487
13. PBPA, 2000. Annual Report, Pharmaceutical Benefits Pricing Authority.
14. Shaked A., Sutton J. Relaxing price competition through product differentiation. Review of Economic Studies. 49:1982;3-13
15. Shaked A., Sutton J. Natural oligopolies. Econometrica. 51:1983;1469-1483
16. Tirole, J., 1988. The Theory of Industrial Organization. MIT Press, Cambridge, Massachusetts, Chapters 2 and 7.
17. Willison, D., Wiktorowicz, P., Grootendorst, P., O'Brien, B., Levine, M., Deber, R., Hurley, J., 2001. International Experience with Pharmaceutical Policy: Common Challenges and Lessons for Canada. Centre for Health Economics and Policy Analysis, Working Paper 01-08, McMaster University.